Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance

Peer Review reports

Original Submission
25 Jan 2021	Submitted	Original manuscript
14 Feb 2021	Reviewed	Reviewer Report
1 Mar 2021	Reviewed	Reviewer Report
16 Mar 2021	Author responded	Author comments - Yuna Sugimoto
Resubmission - Version 2
16 Mar 2021	Submitted	Manuscript version 2
17 Mar 2021	Author responded	Author comments - Yuna Sugimoto
Resubmission - Version 3
17 Mar 2021	Submitted	Manuscript version 3
31 Mar 2021	Reviewed	Reviewer Report
5 Apr 2021	Reviewed	Reviewer Report
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
6 Apr 2021	Editorially accepted
22 Apr 2021	Article published	10.1186/s12888-021-03201-6

Back to article page